Literature DB >> 6713405

Promotion by orotic acid of liver carcinogenesis in rats initiated by 1,2-dimethylhydrazine.

C Laurier, M Tatematsu, P M Rao, S Rajalakshmi, D S Sarma.   

Abstract

Our earlier experiments revealed that orotic acid, a precursor for pyrimidine nucleotides, selectively stimulated the growth of carcinogen-modified liver cells to grow into enzyme-altered hepatocytes (Cancer Lett., 16: 191-196, 1982). The present study was designed to determine whether prolonged feeding of orotic acid will result in hepatocellular carcinoma in initiated rats. Accordingly, groups of rats were given i.p. either 1,2-dimethylhydrazine dihydrochloride (100 mg/kg) or an equivalent volume of 0.9% sodium chloride solution 18 hr after two-thirds partial hepatectomy. After 1 week of recovery, they were continued on either the basal diet or the basal diet containing 1% orotic acid for 10 to 13 months. Some groups of rats, in addition, received a single necrogenic dose of CCl4 8 weeks following exposure to orotic acid diet. The results obtained indicated that 87.5% of initiated rats exposed to orotic acid developed hepatocellular carcinomas in 10 months and 100% in 13 months. Initiated rats exposed to orotic acid diet coupled with a single administration of CCl4 developed 100% hepatocellular carcinoma by 10 months. In contrast, the incidence of hepatocellular carcinoma in initiated rats fed basal diet alone for 13 months was 37.5%, while, in those that received CCl4 in addition, the incidence was 25% in 10 months. Interestingly, a significant number of liver cancers (29 to 36%) in the orotic acid-fed group metastasized to lungs, whereas none of the liver cancers in rats exposed to basal diet metastasized.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713405

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.

Authors:  Atsushi Kudo; Kaoru Mogushi; Tadatoshi Takayama; Satoshi Matsumura; Daisuke Ban; Takumi Irie; Takanori Ochiai; Noriaki Nakamura; Hiroshi Tanaka; Naohiko Anzai; Michiie Sakamoto; Shinji Tanaka; Shigeki Arii
Journal:  J Gastroenterol       Date:  2013-03-30       Impact factor: 7.527

2.  Chronic mitoinhibition during promotion of hepatocarcinogenesis.

Authors:  E Laconi; P M Rao; S Rajalakshmi; P Pani; D S Sarma
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

3.  Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.

Authors:  Helen Winter; Pamela J Kaisaki; Joe Harvey; Edoardo Giacopuzzi; Matteo P Ferla; Melissa M Pentony; Samantha J L Knight; Ricky A Sharma; Jenny C Taylor; James S O McCullagh
Journal:  Cancers (Basel)       Date:  2019-11-28       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.